Sun Pharma (NSE: SUNPHARMA) price as of 20 Nov 2026 close: ₹1,884.9.
Sun Pharmaceutical Industries is India's largest drugmaker and one of the biggest generic pharmaceutical companies in the world. Over the past decade it has transformed itself from a pure generics business into one with a fast-growing portfolio of patented "specialty" medicines, led by the psoriasis drug Ilumya.
Its September 2026 quarter showed healthy sales growth of 12%, strong demand in India and continued specialty growth, but reported profit fell because of large one-time charges. This article separates the one-offs from the underlying business and sets out the Sun Pharma share price target for 2027 to 2030.
Related:HUL target · Maruti target · Axis Bank target · Kotak Bank target · Our methodology
Table of Contents
- Sun Pharma share price target 2027–2030 at a glance
- How Sun Pharma makes money
- Latest results: what changed
- How we calculate the Sun Pharma share price targets
- Sun Pharma share price in 2026: where it stands
- Sun Pharma share price target 2027: ₹1,440 – ₹2,340 (base ₹1,950)
- Sun Pharma share price target 2028: ₹1,520 – ₹2,710 (base ₹2,180)
- Sun Pharma share price target 2029: ₹1,620 – ₹3,150 (base ₹2,450)
- Sun Pharma share price target 2030: ₹1,710 – ₹3,650 (base ₹2,740)
- Key metrics
- Dividends and shareholder returns
- How it compares with other Nifty heavyweights
- The key debate on Sun Pharma
- Risks that would break the base case
- What the numbers suggest
- FAQs on the Sun Pharma share price
1. Sun Pharma share price target 2027–2030 at a glance
All three scenarios come from one transparent formula, explained in the method section below. Targets are for the end of each calendar year.
| Year-end | Bear (₹) | Base (₹) | Bull (₹) |
|---|---|---|---|
| 2027 | 1,440 | 1,950 | 2,340 |
| 2028 | 1,520 | 2,180 | 2,710 |
| 2029 | 1,620 | 2,450 | 3,150 |
| 2030 | 1,710 | 2,740 | 3,650 |
The base case implies a price change of roughly 10% a year from today's ₹1,884.9 to the end of 2030, before dividends.
2. How Sun Pharma makes money
Sun Pharma has four main sources of revenue:
- India formulations: branded generic medicines sold to doctors and pharmacies across India. Sun is the market leader, with particular strength in chronic therapies such as cardiology, diabetes, neurology and psychiatry. India accounts for roughly a third of sales and grew 17% last quarter.
- US business: generic medicines plus specialty brands. The US is about a quarter of sales. Generic prices in the US tend to fall over time, so the specialty portfolio is increasingly important.
- Global specialty: patented drugs including Ilumya (psoriasis and psoriatic arthritis), Cequa (dry eye), Winlevi (acne), Odomzo (skin cancer) and Leqselvi (alopecia). Specialty products now make up over a fifth of total sales.
- Emerging markets and rest of world: branded generics in more than 100 countries, plus active pharmaceutical ingredients (APIs).
Why it matters for the targets: specialty drugs earn much higher margins than generics and are protected by patents for years. As they grow as a share of sales, Sun's overall profitability should rise. The India business provides steady, predictable growth. The main swing factor is the US: generic price erosion, regulatory inspections by the US Food and Drug Administration (FDA) and possible US tariffs on pharmaceutical imports can all hit earnings.
3. Latest results: what changed
| Q2 FY27 (Sep quarter) | Value | Change (YoY) |
|---|---|---|
| Revenue from operations | ~₹16,199 crore | +12% |
| India sales growth | — | +17% |
| US formulation sales | $455 million | −8% |
| Global specialty sales | $356 million | +7% |
| Exceptional charges | ₹1,269 crore | One-off |
| Reported net profit | ~₹1,989 crore | −36% |
Revenue grew about 12% to roughly ₹16,200 crore, helped by a 17% rise in India sales. Global specialty sales rose 7% to $356 million and now account for about 21% of total sales. US formulation sales fell 8% to $455 million, reflecting pressure in the generics business.
Reported net profit fell 36% to about ₹1,989 crore because of exceptional charges of about ₹1,269 crore, including a US antitrust settlement and acquisition-related costs. Excluding these one-offs, the underlying business was far healthier than the headline suggests. In the US, Ilumya also received approval for adults with active psoriatic arthritis, which widens its market.
4. How we calculate the Sun Pharma share price targets
Target = projected EPS × P/E multiple. Each year-end target uses the EPS of the financial year that follows (for example, the 2027 target uses FY28 EPS), because markets price stocks on forward earnings. Read our full methodology.
- Starting EPS: ₹45.71 trailing-twelve-month EPS. This is depressed by one-off charges, so it is a conservative base. Targets use EPS two financial years ahead (year ends in March).
- Bear case: EPS grows 6% a year, P/E 28×. US generics weaken, specialty growth slows and the market pays a lower multiple.
- Base case: EPS grows 12% a year, P/E 34×. India grows in the mid-teens, specialty keeps expanding and one-off charges fall away; multiple close to the forward level.
- Bull case: EPS grows 16% a year, P/E 38×. Ilumya's new indications and new specialty launches accelerate growth, and Sun keeps a premium valuation.
| Financial year | Bear EPS (₹) | Base EPS (₹) | Bull EPS (₹) |
|---|---|---|---|
| FY28 | 51.36 | 57.34 | 61.51 |
| FY29 | 54.44 | 64.22 | 71.35 |
| FY30 | 57.71 | 71.93 | 82.76 |
| FY31 | 61.17 | 80.56 | 96.01 |
Worked example (base, 2027): ₹45.71 × 1.12 × 1.12 = ₹57.34 FY28 EPS → × 34 = ₹1,950.
Sensitivity — 2030 base-case EPS of ₹80.56 at different multiples:
| P/E | 28× | 34× | 38× |
|---|---|---|---|
| 2030 price (₹) | 2,260 | 2,740 | 3,060 |
The sensitivity table shows why the multiple matters as much as earnings: the same 2030 profit can justify very different prices depending on how much investors are willing to pay for it.
5. Sun Pharma share price in 2026: where it stands
With only weeks left in 2026, a year-end "target" is not meaningful. The stock was at ₹1,884.9 on 20 Nov 2026, within a 52-week range of ₹1,583.70 – ₹2,046.90. The shares rose after the results as investors looked past the one-off charges.
6. Sun Pharma share price target 2027: ₹1,440 – ₹2,340 (base ₹1,950)
Based on FY28 EPS of ₹51.36 / ₹57.34 / ₹61.51 (bear / base / bull). What to watch: Ilumya sales after the psoriatic arthritis approval.
7. Sun Pharma share price target 2028: ₹1,520 – ₹2,710 (base ₹2,180)
Based on FY29 EPS of ₹54.44 / ₹64.22 / ₹71.35 (bear / base / bull). What to watch: US generic pricing and any FDA inspection outcomes.
8. Sun Pharma share price target 2029: ₹1,620 – ₹3,150 (base ₹2,450)
Based on FY30 EPS of ₹57.71 / ₹71.93 / ₹82.76 (bear / base / bull). What to watch: Growth of the India business staying in the mid-teens.
9. Sun Pharma share price target 2030: ₹1,710 – ₹3,650 (base ₹2,740)
Based on FY31 EPS of ₹61.17 / ₹80.56 / ₹96.01 (bear / base / bull). What to watch: How much profit margin improves once one-off costs stop.
10. Key metrics
Sun Pharma has net cash on its balance sheet, which gives it room for acquisitions and research spending.
| Metric | Value | Why it matters |
|---|---|---|
| Trailing EPS | ₹45.71 | Depressed by one-offs |
| Trailing P/E | 41.2× | Looks high because of one-offs |
| Forward P/E | 32.4× | Closer to the underlying valuation |
| Specialty share of sales | ~21% | Higher-margin growth engine |
| Dividend yield | 0.85% | Modest income |
11. Dividends and shareholder returns
Sun Pharma usually pays an interim dividend during the year and a final dividend with annual results. Total dividends over the last year were about ₹16 per share, a yield of under 1%. The company prefers to reinvest cash into research, specialty launches and acquisitions, so dividends are a small part of total return.
Investors should expect most returns to come from earnings growth, especially from the specialty business.
12. How it compares with other Nifty heavyweights
| Company | Price (₹) | Trailing P/E | Forward P/E | Dividend yield | 52-week range (₹) |
|---|---|---|---|---|---|
| Hindustan Unilever | 2,052.50 | 32.0× | 40.4× | 2.0% | 1,758 – 2,488 |
| Maruti Suzuki | 14,011 | 32.8× | 29.3× | 1.0% | 10,985 – 17,370 |
| Sun Pharma | 1,884.90 | 41.2× | 32.4× | 0.85% | 1,584 – 2,047 |
| Axis Bank | 1,446 | 15.1× | 13.5× | 0.07% | 1,150 – 1,450 |
| Kotak Mahindra Bank | 515.80 | 23.9× | 27.0× | 0.13% | 345.50 – 516.60 |
Prices as of 20 Nov 2026 close (NSE). The five stocks sit in different sectors, so the table is a valuation snapshot rather than a like-for-like comparison.
13. The key debate on Sun Pharma
The bull argument: Sun has built something few Indian drugmakers have: a profitable global specialty business with patented products. Specialty and India — both higher-margin, more predictable segments — are growing and should keep lifting margins. Once one-off charges fall away, earnings could grow faster than the headline numbers imply.
The bear argument: The US generics business is shrinking and remains exposed to price erosion, regulatory action and possible tariffs. Specialty growth slowed to single digits last quarter, and new launches carry high marketing costs. At more than 30× forward earnings, the valuation already assumes success.
How to tell which side is winning: Watch specialty sales growth each quarter. A return to double-digit specialty growth would support the bull case; continued US declines and slowing specialty would point to the bear case.
14. Risks that would break the base case
- US FDA warning letters or import alerts on Sun's manufacturing plants.
- Faster price erosion in US generics.
- US tariffs or policy changes affecting imported medicines.
- Slower uptake of Ilumya and newer specialty products.
- Further legal settlements or one-off charges.
15. What the numbers suggest
Our base case of ₹2,740 by 2030 assumes 12% annual EPS growth from a base that is temporarily depressed, with a 34× multiple. The range from ₹1,710 to ₹3,650 reflects how much depends on the specialty pipeline and the US business.
Sun is one of the higher-quality Indian pharma companies, but its valuation means execution has to stay strong.
This is a framework, not a recommendation. Your own decision should depend on your time horizon, risk tolerance and existing holdings.
16. FAQs on the Sun Pharma share price
What is the Sun Pharma share price target for 2027?
Our base case is ₹1,950, assuming 12% annual EPS growth and a 34× P/E. The range is ₹1,440 (bear) to ₹2,340 (bull).
What is the Sun Pharma share price target for 2030?
Base case ₹2,740; range ₹1,710 to ₹3,650. It assumes FY31 EPS of about ₹80.56.
Why did Sun Pharma's profit fall in Q2 FY27?
Mainly because of one-time charges of about ₹1,269 crore, including a US antitrust settlement and acquisition costs. Revenue grew 12%.
What is Sun Pharma's specialty business?
Patented medicines such as Ilumya, Cequa, Winlevi and Leqselvi, sold mainly in the US and other developed markets.
Does Sun Pharma pay a dividend?
Yes, usually an interim and a final dividend. The yield is under 1%.
How big is India for Sun Pharma?
India is Sun's largest single market, contributing around a third of sales, and it grew 17% last quarter.
About this analysis: Prepared by the ChartMyWealth Editorial Team using the scenario method described in our methodology. Prices and results were reviewed on 20 Nov 2026, and targets are reviewed after each results announcement.
Disclaimer: This article is for educational purposes only and is not investment advice or a recommendation to buy or sell any security. Price targets are scenario estimates based on the stated assumptions and may not materialise. Please consult a SEBI-registered investment adviser before making investment decisions.
Leave a comment
Your email address will not be published. Required fields are marked *
